Literature DB >> 29491128

Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee.

Pier Mannuccio Mannucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29491128      PMCID： PMC5830372          DOI： 10.3324/haematol.2018.187567

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  CHANGES IN THE ACTIVITY OF ANTIHEMOPHILIC A FACTOR (F. VIII) AND IN THE BLEEDING TIME ASSOCIATED WITH MUSCULAR EXERCISE AND ADRENALIN INFUSION.

Authors:  O EGEBERG
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

Authors:  J D Cash; A M Gader; J da Costa
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

3.  Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.

Authors:  P M Mannucci; M Aberg; I M Nilsson; B Robertson
Journal:  Br J Haematol       Date:  1975-05       Impact factor: 6.998

Review 4.  Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

Authors:  Johannes Oldenburg
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

5.  Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients.

Authors:  G Mariana; N Ciavarella; M G Mazzucconi; S Antoncecchi; S Solinas; P Ranieri; P Pettini; F Agrestini; F Mandelli
Journal:  Clin Lab Haematol       Date:  1984

6.  Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Authors:  Corien L Eckhardt; Alice S van Velzen; Marjolein Peters; Jan Astermark; Paul P Brons; Giancarlo Castaman; Marjon H Cnossen; Natasja Dors; Carmen Escuriola-Ettingshausen; Karly Hamulyak; Daniel P Hart; Charles R M Hay; Saturnino Haya; Waander L van Heerde; Cedric Hermans; Margareta Holmström; Victor Jimenez-Yuste; Russell D Keenan; Robert Klamroth; Britta A P Laros-van Gorkom; Frank W G Leebeek; Ri Liesner; Anne Mäkipernaa; Christoph Male; Evelien Mauser-Bunschoten; Maria G Mazzucconi; Simon McRae; Karina Meijer; Michael Mitchell; Massimo Morfini; Marten Nijziel; Johannes Oldenburg; Kathelijne Peerlinck; Pia Petrini; Helena Platokouki; Sylvia E Reitter-Pfoertner; Elena Santagostino; Piercarla Schinco; Frans J Smiers; Berthold Siegmund; Annarita Tagliaferri; Thynn T Yee; Pieter Willem Kamphuisen; Johanna G van der Bom; Karin Fijnvandraat
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

7.  1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

Authors:  P M Mannucci; Z M Ruggeri; F I Pareti; A Capitanio
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321

8.  DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.

Authors:  A I Warrier; J M Lusher
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

9.  DDAVP challenge tests in boys with mild/moderate haemophilia A.

Authors:  Shoshana Revel-Vilk; Victor S Blanchette; Cathy Sparling; Ann Marie Stain; Manuel D Carcao
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

10.  Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Authors:  Janneke I Loomans; Marieke J H A Kruip; Manuel Carcao; Shannon Jackson; Alice S van Velzen; Marjolein Peters; Elena Santagostino; Helen Platokouki; Erik Beckers; Jan Voorberg; Johanna G van der Bom; Karin Fijnvandraat
Journal:  Haematologica       Date:  2018-01-05       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.